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For most cases of endogenous depression (major depression), the hypothesis of 
monoamine deficiency, despite a number of limitations it faces, is still considered 
the most acceptable explanation. The main difficulty faced by this hypothesis is the 
reason for the decrease in the level of cerebral monoamines (primarily serotonin) 
during depression. It is assumed either increased activity of the MAO enzyme, 
which metabolizes serotonin, or a mutation with the loss of function of the gene of 
the Tph-2 enzyme, which synthesizes serotonin, as possible causes. In this review, 
a third cause is proposed, which can explain a number of cases of «spontaneous» 
onset of depressive symptoms in apparently healthy people, as well as links the 
hypotheses of “monoamine deficiency” and “disturbances in circadian rhythms.” 
It is assumed that the formation of endogenous depression is due to a combination 
of two factors: a reduced “basal” level of cerebral serotonin and excessively long 
pre-morning periods of REM sleep, during which the release of cerebral mono-
amines stops altogether. As a possible way to of non-drug treatment of depression, 
not deprivation, but fragmentation of this phase of sleep is suggested, that is much 
easier for patients to tolerate.
Keywords: serotonin, sleep, rem sleep, depression, monoamine hypothesis
1. Introduction
A hypothesis is put forward according to which two factors play an important 
role in the formation of a number of cases of so-called “endogenous” (major) 
depression. First, the initially lowered (but within the reaction norm) level of 
cerebral serotonin, reflecting the gene polymorphisms of the human population. 
Second, the excessively long pre-morning periods of REM sleep associated with the 
“pressure of civilization” on the natural structure of the human wakefulness-sleep 
cycle, during which the release of cerebral monoamines stops altogether. It is a 
combination of these two factors that can lead to the emotional imbalance seen in 
depression.
2. Serotonin and sleep
Serotonin (5-HT) is one of the oldest and most important mediators in the 
 central nervous system, participating in a wide range of behavioral, physiologi-
cal and pathological processes. The history of its study goes back about 70 years, 
nevertheless, serotonin remains one of the most mysterious neurotransmitters.  
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As is known, the largest accumulation of serotonergic neurons in the brain is 
observed in the dorsal raphe nuclei (DRN) and the pons varolii (zones B6 and B7 
according to Dahlström & Fuxe [1]). The total number of such cells in human brain 
is relatively small - about one hundred thousand. The serotonergic system has two 
characteristics: first, the unusually numerous ramifications of its axons (up to a 
million bifurcations of a single axon). Secondly, the extraordinary variety of types 
(at least 7) and subtypes (at least 14; some researchers even count more than 20) 
of their receptors, among which there are both membrane depolarizing (subtypes 
5-HT2A-C, 5-HT3, 5-HT6, 5-HT7) and hyperpolarizing it (5-HT1A,B). Due to the 
abundant “treelike” branching, several hundred thousands of serotonergic neurons 
of the brain stem innervate tens of billions of other neurons in the human brain: 
practically all the nerve cells of the neocortex, hippocampus, striatum, and hypo-
thalamus, other parts of the brain as well as motor neurons of the spinal cord [1, 2]. 
Only the upper olive complex (part of the auditory system) and the optic chiasm 
are devoid of serotonin afferents [3]. And due to the receptor diversity, ligands of 
serotonin receptors can effect both activating and inhibitory processes on the brain 
and behavior in general.
The role of serotonin transmission in the regulation of wakefulness and sleep 
was first identified by the work of Michel Jouvet and his laboratory in Lyon, France. 
In these experiments of the classic of world somnology, performed on cats using 
primitive technologies of the 60s - early 70s of the last century, the following was 
shown. Intracerebral administration of serotonin, or electro-stimulation of the 
DRN or the median raphe nucleus (MnRN), where most 5-HT neurons in the brain 
are located, induces a short period of paradoxical (REM) sleep, followed by pro-
longed deep slow-wave sleep (NREM). If, on the contrary, the level of cerebral sero-
tonin is reduced by systemic administration of parachlorophenylalanine (PCPA), 
which blocks serotonin synthesis, or by destruction of the MnRN, both phases of 
sleep are sharply reduced. This insomnia lasts at least 10 days. In this case, effect of 
PCPA is eliminated by the administration of the precursor of serotonin - 5-hydroxy-
tryptophan. These and other early experiments served as the basis for Michel 
Jouvet’s hypothesis about serotonin as “somnotonin” (as it was then called by the 
Swiss somnologist Werner Koella), the main factor in slow wave sleep [4]. However, 
further experiments performed in the same laboratory of Jouvet with electrical 
stimulation and reversible shutdown of DRN neurons caused by local tissue cool-
ing to 10 °C, pointed, on the contrary, to serotonin as a factor of wakefulness. 
Eventually, it was proved that this hypothesis of Jouvet was wrong - in particular, 
insomnia caused by suppression of serotonergic neurotransmission was associated 
with a disorder of thermoregulation, a drop in body temperature, which led to an 
increase in the motor activity of cats to warm up [5]. And the insomnia that occurs 
in experimental rats and cats as a result of the administration of PCPA, as it turned 
out, is the result of a sharp increase in sensitivity to the surrounding animal stimuli, 
and not a disorder of the regulation of the wakefulness-sleep cycle [6].
Summing up the results of many years of research, a disciple of Michel Jouvet, 
Raymond Cespuglio, suggested that serotonin may be involved in the regulation 
of the wakefulness-sleep cycle in two different ways: in wakefulness serotonin 
is realized on the presynaptic membrane of the 5-HT neurons and promotes the 
formation and accumulation in target cells hypnogenic neuropeptides: vasoin-
testinal polypeptide (VIP), corticotropin-like intermediate lobe peptide (CLIP), 
substance P (SP); in the subsequent period of sleep, under the influence of these 
peptides, dendritic (nonsynaptic) realization of serotonin in the nuclei of the raphe 
occurs and its binding to the 5-HT1B autoreceptors, as a result of which the synaptic 
release of serotonin is weakened and stopped [3]. However, this hypothesis also has 
not received convincing experimental confirmation [6].
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Experiments with extracellular registration have shown that most serotonergic 
neurons are very active in the waking state, and during the transition to sleep and 
further into deep NREM sleep, they progressively slow down their activity and 
completely “silence” immediately before the transition to REM sleep. Thorough 
studies of the activity of not only large and medium-sized, but also small cells of 
the dorsal raphe of the model mouse brain in the wake–sleep cycle, carried out by 
Jouvet’s disciple Kazuya Sakai, revealed a high anatomical, neurochemical and func-
tional heterogeneity of these neurons. The majority of neurons in this area (52%) 
are indeed serotonergic (5-HT/DR), and almost all of them (48%) are active only in 
wakefulness, but a significant part (25% of all cells) are active in sleep, and judg-
ing by the spike shape, 19% of them are GABAergic, and only 6% are serotonergic 
[7]. Apparently, serotonin neurons are mainly responsible for maintaining calm 
(relaxed) wakefulness; thus, according to some data, they are most active during 
food consumption and reduce the frequency of impulses with increased behavioral 
activation [5].
Agonists of all serotonin receptors stimulate wakefulness and suppress NREM 
and REM sleep when administered systemically or intraventricularly. In this case, 
the activation of wakefulness occurs by depolarizing the histaminergic tuberomam-
millary neurons of the posterior hypothalamus, as well as GABA/parvalbumin-con-
taining neurons of the basal forebrain region, which project into the hippocampus 
and neocortex. Suppression of NREM is carried out mainly by inhibition of neurons 
in the “sleep center” VLPO, mediated by the 5-HT1A receptor [5]. And the suppres-
sion of REM sleep occurs due to inhibition of cholinergic REM-on neurons of the 
pons [5].
With direct microinjection of inhibitory receptor 5-HT1A agonists into the 
dorsal raphe nuclei, an increase in REM sleep occurs, whereas similar injections 
of inhibitory autoreceptor 5-HT1B agonists and activating 5-HT2A/C, 5-HT3 and 
5-HT7 receptors suppress REM sleep, which is consistent with the concept of the 
need for inhibition of 5-HT neurons to trigger REM sleep [8]. Systemic administra-
tion of non-selective antagonists of the 5-HT2A/C receptors, selective antagonists 
or reversible agonists of the 5-HT2A receptor in laboratory rats and mice, healthy 
subjects and patients with primary or comorbid insomnia causes an increase in 
NREM sleep, which, again, is consistent with the idea of the participation of 5-HT 
neurons in maintaining wakefulness [6].
Thus, according to the results of neural and pharmacological studies, serotonin 
seemed finally established as the status of a wakefulness mediator along with other 
monoamines (norepinephrine, dopamine, histamine), as well as acetylcholine and 
glutamate. The main source of serotonin - the DRN – were introduced on diagrams 
as one of the clusters of the reticular ascending activating system [9, 10]. It has 
also been shown to play an important role in the negative regulation of REM sleep: 
without turning off serotonin transmission, neither initiation nor maintenance of 
REM sleep is possible [6].
In this case, selective shutdown of serotonergic transmission should suppress 
wakefulness by increasing NREM sleep. Such a methodological opportunity 
appeared with the introduction of molecular genetic and other newest innovative 
techniques into neurophysiology. It was found that the brain has its own special 
isoform of the enzyme tryptophan hydroxylase - Tph2, which converts the amino 
acid tryptophan, which is supplied to the body with protein food, into 5-hydroxy-
tryptophan, a precursor of serotonin, and encoded by a separate gene. This discov-
ery made it possible to create knockout mice for this gene, in which the content of 
cerebral serotonin does not exceed 4% of its content in the brain of control mice 
(that is, practically absent). Figuratively describing the phenotype of such mice, 
which grew up “without serotonin in their brain”, can be named as “evil dwarfs.” 
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They are fertile and females have milk, but they do not care for their offspring, and 
therefore half of their offspring dies [11, 12]. Disorders of the wakefulness-sleep 
cycle in these mutants are limited, judging by the results of registration of locomo-
tor activity, to a slight increase in sleep and suppression of wakefulness in daylight 
(daytime), which seems to correspond with the above hypothesis [13].
At the same time, in another study on genetically modified mice with the 
homozygous Tph2 mutation (intact neurons, but complete absence of serotonin 
in the central nervous system) and polysomnographic registration, the following 
was found. A small (but statistically significant) decrease in the duration of NREM 
sleep and a corresponding increase in active wakefulness in mutant animals com-
pared with control occurred only when the light was turned on and off. Apparently, 
the absence of serotonin increases the reactivity of the animal to light stimulation. 
It was also shown that the sleep of the mutants was less fragmented. No further dis-
turbances in the wake–sleep cycle were identified. In this series of experiments, the 
absence of serotonin caused only very small changes, not confirming the original 
hypothesis [14].
However, Tph2 knockout mice cannot serve as an adequate model for study-
ing the role of serotonin in the regulation of the wakefulness-sleep cycle, since 
it is unclear whether the revealed phenotypic changes are the result of abnormal 
development, compensation for the lack of serotonin by other transmitters, or, 
indeed, impaired neurotransmission in adults. To solve this problem, a method 
was developed to turn off the expression of the Tph2 gene by microinjection of its 
blocker directly into the tissue of the raphe nuclei of the midbrain and pons in the 
genetically created mouse strain [15]. By visual analysis of video recordings, it was 
possible to reveal an increased level of motor activity, especially noticeable in the 
night (active) phase of the nychthemeron, when in the second half of the night 
the control individuals experienced a period of decreased activity, called by the 
authors “siesta”. In mice with blocked serotonergic transmission, such periods were 
absent altogether; they ran almost continuously all night [15]. Thus, according to 
the results of this study, serotonin itself behaves more like “sleep factor” than “wake 
factor”.
Since 5-HT containing neurons also secrete glutamate and various neuropep-
tides, the effect of their destruction may be quite different from that of the elimi-
nation of serotonin itself. In the work of Japanese authors [16], carried out using 
polysomnographic recording, neurotoxic destruction of serotonin-containing DR 
neurons in special genetically engineered mice led to a decrease in REM sleep at 
night, when its representation is already low. In addition, according to the data of 
the same authors, in the experimental mice, in comparison with the control ones, 
the response to the new environment was weakened and the power of the theta 
rhythm in wakefulness was increased. However, all these effects were so small that 
they were detected only with the help of statistical tricks. This, however, did not 
prevent the authors from concluding that their data support the main hypothesis 
about the role of serotonin as a factor of wakefulness (positive) and REM sleep 
(negative), presented above.
Finally, in a recently published study led by renowned Boston somnologist 
Patrick Fuller using a novel method of highly selective chemogenetic activation 
of serotonergic neurons in the DRN in combination with polysomnography and 
behavioral tests, no unambiguous results were obtained either [17]. A “compensa-
tory” restoration of NREM sleep, slightly suppressed by the 5-HT neuron activator 
injection procedure, was shown to return to baseline levels. This effect can hardly be 
called somnogenic, but it is definitely not activating. In addition, a change in behav-
ior in the open field was found, which the authors interpret as a decrease in the level 
of anxiety under the influence of the activation of serotonergic neurons in the DRN. 
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However, testing in a cruciform elevated maze revealed no changes. The authors 
refer to a recent study that revealed the existence of two mutually intertwining 
serotonergic subsystems in the DRN that innervate the orbital frontal cortex and 
the central amygdala differently. One of these subsystems supports anxiogenic and 
the other anxiolytic functions. It is possible that the simultaneous activation of 
both subsystems is associated with the uncertainty of the results obtained in such 
experiments [17].
As mentioned above, most serotonin-secreting neurons are “silent” during the 
entire period of REM sleep until the moment of its completion (by awakening or 
re-entering NREM sleep), and in fact not one single serotonin molecule is released 
from the presynaptic membrane during this time.
As can be seen from the Table 1, the intercellular fluid in wakefulness is satu-
rated mainly with the mediators with depolarizing action on the postsynaptic mem-
brane. During the transition to NREM sleep, all these molecules quickly disappear 
from the intercellular environment being replaced by the main inhibitory mediator 
of the brain, GABA, that concentration increases with the deepening of NREM 
sleep, and the peptide galanin colocolized with GABA. The cerebral biochemical 
environment in REM sleep is special. High levels of acetylcholine, glutamate and 
galanin are combined with a complete absence of orexin (hypocretin) and mono-
amines — serotonin, norepinephrine and histamine, with the exception of dopa-
mine, the concentration of which may sometimes even exceed that in wakefulness. 
A new mediator appears, the MCH peptide, which mediates the hypothalamo-pon-
tine level of REM sleep regulation. The release of GABA in general is significantly 
reduced, but remains high in areas of the orexinergic (LHA), histaminergic (TMN), 
serotonergic (DR) and noradrenergic (LC) neurons localization. In these systems, 
GABAergic neurons play the role of a “lock” preventing depolarization of these cells 
during the entire period of REM sleep.
Neurotransmitters Localization W NREM sleep REM sleep
5-HT DR ↑↑ ↓→↓↓ ↔
Norepinephrine LC ↑↑ ↓→↓↓ ↔
Histamine TMN ↑↑ ↓→↓↓ ↔
Dopamine VTA/SNpc/vPAG ↑↑ ↓ ↑
Acetylcholine LDT/PPT/BF ↑↑ ↓→↓↓ ↑↑
Glutamate PC/PB/BF ↑↑ ↓→↓↓ ↑↑
GABA Total brain ↑/↓ ↑↑ ↑/↓
Orexin/Hypocretin LHA ↑↑ ↔ ↔
Galanin VLPO/MnPO ↓ ↑↑ ↑↑
MCH LHA/PH ↓ ↓ ↑↑
Abbreviations: W – wake; NREM sleep – non rapid eye movement sleep; REM sleep - rapid eye movement sleep; 
5-HT – serotonin; GABA – γ-aminobutyric acid; MCH – melanin-concentrating hormone; LC – locus coeruleus; DR 
– dorsal raphe; TMN – tubero-mammillar nucleus; VTA – ventral tegmental area; SNpc – substantia nigra/pars 
compacta; vPAG – ventral periaquetuctul gray matter; LDT/PPT – latero-dorsal tegmentum/pedunculo-pontine 
tegmentum; BF – basal forebrain; PC/PB – preceoruleus/parabrachialis nuclei; LHA – lateral hypothalamic area; 
VLPO – ventro-lateral preoptic area; MnPO – median preoptic area; PH – posterior hypothalamus; ↑ – increase 
in release; ↓ -decrease in release; ↑↑ - substantial increase in release; ↓↓ - substantial decrease in release; ↑/↓ 
- increase or decrease in release dependently of the site of cerebral localization; → – gradual decrease in release; ↔ – 
release ceased.
Table 1. 
A simplified scheme for the secretion of cerebral neurotransmitters in the sleep–wake cycle (data from animal 
studies).
Serotonin and the CNS - New Developments in Pharmacology and Therapeutics
6
Obviously, the level of serotonin (as well as norepinephrine and histamine) at 
the sites of projection of aminergic neurons (and, possibly, in the brain as a whole) 
can decrease during this time. However, the periods of REM sleep in all animals 
are short, and in some species (small rodents, birds, etc.) they are extremely short 
(from a few seconds to 1 min) [18, 19]. So this decrease cannot be significant, and 
in the subsequent period of wakefulness, the normal, “basal” level of serotonergic 
transmission is quickly restored.
The situation is different in humans. In adults, unlike animals, sleep is of a 
continuous, so-called “monophasic” or “consolidated” nature. This means that an 
adult living in modern urban conditions is waking all day (16 hours), and the entire 
daily “quota” of sleep, usually 5 cycles 1.5 hour each, is realized at night “at a time.” 
In this case, the first half of the night sharply differs from the second - and this is 
another important difference between human sleep and animal sleep (Figure 1, 
upper graph). In the first half of the night, a person implements mainly the need 
for deep slow wave sleep (NREM), which has accumulated over a long period of 
wakefulness (stage 3; according to the old classification - stages 3 + 4, “delta sleep” 
is apparently a state that is critical for the survival of the organism). In the second 
half of the night, the need for REM sleep is realized, which alternates with periods 
of superficial NREM sleep (stage 2). At the same time, individual periods of REM 
Figure 1. 
A hypnogram of a healthy human subject (top) and a depressed patient (bottom) [20]. W - wakefulness, 
REM - REM sleep, S1-S4 - stages of NREM sleep, MT and BM - various types of movements during sleep, 
EM - rapid eye movements. It can be seen that the patient has fragmented sleep, REM sleep is disinhibited, and 
deep NREM sleep (stages 3 and 4; according to the new classification, they combined into one), on the contrary, 
is suppressed.
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sleep, which in a healthy person occupies about 2 night hours, can last 20, 30, and 
even 40 minutes in the last sleep cycles [20]. Naturally, such long periods of inactiv-
ity of the “serotonin factory” of the brain cannot pass without leaving a trace.
What determines these differences in the structure of human sleep? A newborn 
baby sleeps around the clock with short sucking breaks, total about 16 hours, 8 
of which is occupied by the so-called “activated sleep”, which is considered as the 
precursor of adult REM sleep. A one-year-old child has two periods of daytime 
sleep, and a four-year-old is allowed to sleep only once a day, after lunch. An eight-
year-old is already attending school and cannot sleep during the day, and this daily 
rhythm (without daytime sleep) is maintained by the majority of the modern urban 
population for life. Psychophysiological studies of the wakefulness-sleep rhythm 
carried out at one time in healthy subjects who were transferred to a 24-hour bed 
rest when isolated from the external environment [21], as well as some observations 
of ethnographers on the nature of sleep in primitive tribes living in isolation from 
civilization [22], allow to make the following assumption. By nature, a person has 
a sleep–wake rhythm with two periods of short naps. With this mode, the duration 
of night sleep is significantly shortened; a person can get up at dawn (in summer). 
Sleep becomes less consolidated, sleep cycles can be interspersed with more or less 
prolonged episodes of wakefulness. The differences between the first and second 
half of the night are smoothed out. In general, human sleep begins to resemble more 
animal sleep [21–23]. The monophasic nature of sleep of a modern person, appar-
ently, is associated not so much with biological, genetic factors, as with the “pres-
sure of civilization”, distorting, disrupting the natural alternation of wakefulness 
and sleep. During a 16-hour daytime period of continuous wakefulness, a modern 
person experiences repeated “intrusions” of sleep mechanisms, realized in the form 
of episodes of local sleep, microsleep and an increase in the delta index in the EEG 
[24]. A monophasic diurnal rhythm (without daytime sleep) is acquired by the 
majority of the modern urban population in childhood and retained for the rest of 
their lives [25].
Thus, the circadian rhythm of a modern urban person is 16 hours of sleep 
deprivation, followed by 8 hours of sleep. And the law of “rebound” is as follows: 
first, delta sleep is restored (stage 3), then REM sleep [26]. On the other hand, 
superficial sleep is considered an “optional” state, which “can be dispensed with.” 
Consequently, the unusually long pre-morning periods of REM sleep, in which 
serotonergic transmission can be severely depleted, are mainly due to “civilization 
pressure” disrupting natural circadian dynamics.
3. Serotonin and depression
Although the role of serotonin in the regulation of the wakefulness-sleep 
cycle remains not completely defined, its participation in emotional reactions is 
well known. In popular literature, serotonin is often referred to as the “happiness 
hormone”. Excessive activation of serotonergic transmission in the brain causes 
movement disorders – part of the so-called “serotonin syndrome”, and insufficient 
activation seems associated with diseases such as depression, schizophrenia, anxiety 
disorders, etc. [27, 28]. In the 50–60s of the last century, the so-called “catechol-
aminergic” hypothesis became widespread, linking the occurrence of depression 
with a lack of noradrenergic transmission. It was replaced by the “serotonin” 
hypothesis of endogenous depression, which was first published in the Lancet 
magazine in an article by a psychopharmacologist from Leningrad (USSR, now 
St. Petersburg, Russia) Izyaslav (Slava) Lapin and his graduate student Gregory 
Oxenkrug: “Intensification of the central serotoninergic processes as a possible 
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determinant of the thymoleptic effect” [29]. The article had about 350 citations in 
the first 18 years (to date, according to Google searches, about 800). This led Eugene 
Garfield to include it in the “This Week’s Citation Classic” section of the Current 
Contents and to publish a note by Oxenkrug on how the article was created [30].
Lapin and Oxenkrug were the first to link emotional disorders and sleep 
disturbances in depression with a common causative factor - impaired serotonin 
transmission due to changes in the turnover of cerebral serotonin. Reducing 
serotonergic transmission in the brain through the hypothalamus-pituitary–adrenal 
cortex axis disinhibits the release of cortisol. Cortisol activates the enzyme tryp-
tophan dioxygenase (TDO), which “shunts” the normal turnover of serotonin and 
converts it (in the presence of the pro-inflammatory cytokine γ-interferon, which 
appears in response to stress) into kynurenine. As a result, serotonin is released less 
and less. Neuroactive kynurenines, in turn, increase anxiety and impair cognitive 
performance. Subsequently Lapin showed that the metabolism of kynurenine in the 
absence of vitamin B6 leads to the appearance of diabetogenic derivatives [31]. The 
impact of Lapin’s ideas on the further development of world psychiatry and psycho-
pharmacology was described in detailed reviews by Oxenkrug [32, 33].
Later, other authors developed a “new serotonin hypothesis” [34], according to 
which an increased level of glucorticoids, systemic inflammatory processes, and 
neuroimmune activation of microglia stimulate the synthesis of enzymes trypto-
phan dioxygenase and indoleamine dioxygenase (TDO/IDO) and finally shift the 
breakdown of tryptophan to the kynurenine pathway. Finally, the initial develop-
ment of Lapin recently received a new generalization in the form of the so-called 
“serotonin-kynurenine-inflammatory” hypothesis of the onset of depression (see 
Figure 2) [35, 36]. Based on the latest biochemical and molecular biology studies, 
these authors show that the metabolites of kynurenine - oxidized kynurenine, 
quinolinic acid and the cation NAD+ (nicotinamide-adenine-dinucleotide), which 
have exito- and neurotoxic properties, cause an excessive increase in glutamatergic 
neurotransmission, suppressing neurogenesis in the fascia dentata of the hippo-
campus, apoptosis and neurodegeneration. The kynurenine pathway of serotonin 
metabolism occurs in microglia, and the proliferation of microglia has been found 
in a number of studies using neuroscanning of depressed patients. So, despite the 
fact that modern theories of the origin of depression concentrate more on neuroin-
flammatory and neurodegenerative processes [36–39], Lapin’s serotonin idea, put 
forward more than half a century ago has not lost its relevance.
Back in 1960, a reduced (almost 3 times) level of serotonin in the cerebrospinal 
fluid of depressed patients was confirmed [40]. And selective serotonin reuptake 
inhibitors (increasing 5-HT concentration in the synaptic cleft) have been widely 
and successfully used in clinical medicine as antidepressants for more than 30 years 
[2]. However, the generalizing works of the last two decades have given some 
authors the basis for a paradoxical conclusion that not suppression, but, on the 
contrary, the excess of serotonin neurotransmission is the cause (or at least one of 
the causes) endogenous depression (melancholy), or that serotonin is not involved 
at all in the pathogenesis of this disease [41–44].
In recent years, researchers have turned their attention not to cerebral serotonin 
itself, but to its carrier protein (5-HTT) and the gene for this protein. It turned out 
that people homo- or heterozygous for its short allele are less resistant to stress and 
are more at risk of developing insomnia and depression than carriers of the long 
allele [45]. The short allele is associated with a decrease in the number of 5-HTT 
binding regions on the surface of the presynaptic membrane and, accordingly, in 
the reuptake of excess serotonin. From this point of view, the disorder of serotonin 
transmission in some types of depression, in fact, may be associated more with an 
excess than a lack of serotonin in the synaptic cleft.
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Apparently, under the general term “depression” there is several (and maybe 
even many) diseases of various etiologies [46]. At the same time, the majority of 
patients respond positively to the intake of selective serotonin reuptake inhibitors 
(SSRIs). Moreover, almost any drug that inhibits the reuptake of monoamines 
(primarily serotonin, but partly also norepinephrine and dopamine) has thymo-
leptic (antidepressant) properties [46]. However, a very long interval (calculated 
in weeks) from the start of antidepressant administration to the appearance of a 
therapeutic effect is an indirect indication that the lack of monoaminergic transmis-
sion is most likely a secondary, “downward” consequence of some still unknown 
primary disorders [46]. Nevertheless, for most cases of endogenous depression 
Figure 2. 
Simplified illustration of the kynurenine pathway. Tryptophan (TRP) is predominantly converted into 
kynurenine (KYN) by the indoleamine 2,3-dioxygenase (IDO) isozymes and tryptophan dioxygenase (TDO). 
IDO-1 is expressed in various immune cells throughout the body, notably dendritic cells, monocytes, and 
macrophages. Less is known about the more recently discovered IDO-2 enzyme although it is more selectively 
expressed in dendritic cells, liver, kidney, and the brain and it does not appear to have a significant effect 
on peripheral kynurenine concentration. TDO-2 is an alternative nomenclature for TDO. KYN can be 
metabolized into kynurenic acid (KYNA), which is usually considered to be neuroprotective, by the KAT 
isozymes. Alternatively, it may be converted into anthranilic acid by kynureninase or 3-hydroxykynurenine 
(3HK) by kynurenine monooxygenase (KMO). Metabolism down the latter pathway increases under 
inflammatory conditions. 3HK is a free radical generator while quinolinic acid (QA) is a known neurotoxin 
and gliotoxin. Thus, metabolites in this pathway are usually considered to be neurotoxic. QA is the endogenous 
source of nicotinamide and nicotinamide adenine dinucleotide (NAD+) [35].
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(major depression), the hypothesis of monoamine deficiency is still considered the 
most acceptable [46]. Apparently, the impairment of serotonergic neurotransmis-
sion is one of the links in a cascade of molecular biological events that ultimately 
lead to neuroinflammatory and neurodegenerative changes in certain parts of the 
brain, as mentioned above.
The main difficulty faced by this hypothesis is the reason for the decrease in sero-
tonin levels in the brain during depression. Among the possible reasons, either an 
increased activity of the MAO enzyme, which metabolizes serotonin, or a mutation 
with loss of function of the gene of the Tph-2 enzyme, which synthesizes serotonin, 
is proposed. In this review, we propose a third reason that can explain a number of 
cases of “spontaneous” onset of depressive symptoms in apparently healthy people, 
as well as link the hypotheses of “monoamine deficiency” and “circadian rhythm 
disturbances” [46].
4. Sleep and depression
Depression is one of those relatively few diseases that are characterized by 
pronounced and rather specific sleep disorders. In addition, these disorders can 
occur much earlier than the main symptoms (mood disorders, etc.), and therefore 
serve as important predictors of the disease. Non-specific disorders in depression 
include difficulty falling asleep, frequent nighttime awakenings, and early morn-
ing awakenings. However, there is a more specific violation of the sleep structure: 
suppression of deep NREM sleep (stage 3) and disinhibition of REM sleep (see 
Figure 1, lower graph). The suppression of deep SWS manifests itself in the loss of 
stage 4 (according to the old classification), reduction and fragmentation of stage 
3, a decrease in the EEG delta index, and lengthening of stage 2. The disinhibition 
of REM sleep is manifested both quantitatively and qualitatively. Quantitatively, by 
reducing the latency of the onset of the first REM period down to zero, when sleep 
can begin with a REM episode, which never happens in a healthy adult; lengthening 
the first REM period; an increase in the proportion of the total duration of REM 
sleep in all night sleep. Qualitatively, the disinhibition of REM sleep manifests 
itself in an increase in the generation of rapid eye movements already in the first 
REM sleep period. Although similar disorders of REM sleep are observed not in all 
patients with depression, but only in 50–70% (according to various sources), and 
similar phenomena of REM sleep “disinhibition” can sometimes be observed in 
other neuropsychiatric disorders (schizophrenia, manic psychosis), nevertheless for 
“major” depression, they are much more typical and more pronounced [37].
As noted above, suppression of neurogenesis in adult animals was shown in 
various experimental models of depression (mice, rats) [47]. Interestingly, in other 
models associated with an increase in REM sleep (some forms of stress), according 
to some data, neurogenesis in the hippocampus is also impaired. On the other hand, 
inhibition of neurogenesis is also observed in sleep deprivation [37].
One of the main arguments in favor of the hypothesis of a causal relationship 
(rather than just a correlation) between depression and REM sleep is the effects of 
antidepressants. It is well known that most antidepressants that prevent the natural 
breakdown of serotonin (and other brain amines): tricyclic drugs, selective serotonin 
reuptake inhibitors (SSRI), deeply inhibit REM sleep. Especially effective in this 
regard are MAO inhibitors, which can almost completely eliminate REM sleep for 
months and years [37–39]. Millions of patients around the world have taken and 
are taking these drugs. No cases of cognitive impairment were reported; instead, 
there is some evidence that MAO inhibitors even improve memory! On the contrary, 
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the latest generation of benzodiazepines, used as hypnotics and practically do not 
disturb the duration and distribution of REM sleep, have a pronounced detrimental 
effect on memory due to the effect of these drugs on the GABA signaling system 
[48–51].
Now, imagine that in the human population, with its unusually wide gene 
diversity, there are subjects with initially lowered levels of cerebral serotonin. This 
may be due to some gene polymorphisms that cause, for example, the synthesis 
from dietary tryptophan, not serotonin, but kynurenines (as Lapin believed) 
[29, 31–33]), or a decrease in the formation of tryptophan hydroxylase-2, which 
synthesizes cerebral serotonin from its precursor, or an increased level of the 
MAO-A enzyme, which metabolizes serotonin, etc. For such people, long pre-
morning periods of REM sleep become especially dangerous, since they can reduce 
the level of cerebral serotonin below a certain critical level, the threshold for 
disruption of general serotonergic transmission and the occurrence of emotional 
disorders. This approach is confirmed by the subjective reports of patients report-
ing the appearance of the first feelings of depression even during the experience of 
morning dreams and reaching their maximum severity immediately upon awaken-
ing. However, by the evening (as cerebral serotonin accumulates in the course of a 
vigorous state), the patient’s condition gradually improves, depressive symptoms 
go away by themselves, and he/she feels completely healthy ... until a new period of 
sleep comes! [46]. It is clear that against the background of a low, near-threshold 
level of cerebral serotonin, even immersions in NREM sleep causing a decrease in 
serotonin release can re-launch pathological processes in the brain.
On the other hand, the release of cerebral serotonin is involved in the inhibi-
tion of the glutamatergic/cholinergic center of REM sleep triggering in the pons 
[5, 9, 10]. Then, the weakening of this inhibition may be associated with a well-
studied increase in the “pressure” of REM sleep in depression, which manifests 
itself, in particular, in the shortening of the latent period of the first episode of this 
sleep phase, as mentioned above [37–39]. Moreover, according to some reports, 
even genetic relatives of such patients, who do not suffer from depression, but, 
assuringly might have the same gene polymorphism and, as a result, a lowered 
“basal” level of cerebral serotonin, also have excessively prolonged periods of REM 
sleep [37]. That is, one can assume that all people who initially have a lowered level 
of cerebral serotonin, due to this, have an increased “pressure” of REM sleep, which 
further lowers this level.
It becomes clear why it is not possible to create a more or less adequate experi-
mental model of stress-induced anhedonia (depression) [52]. For this, apparently, 
it is necessary to adapt the experimental mice to “human conditions”: a constant 
16-hour sleep deprivation (in the dark period of the day) accompanied by its 8-hour 
“return” (in the light period). And it is necessary to influence chronic stress also 
in the dark period against the background of this artificial circadian rhythm. It is 
possible that in this case the applied impacts will be more effective.
5. Conclusion
Thus, according to the proposed hypothesis, the formation of depression is 
due to a combination of two factors - a reduced level of cerebral serotonin and the 
structure of human night sleep with extremely long pre-morning periods of REM 
sleep. It is known that total sleep deprivation (or selective REM sleep deprivation) 
is used as an effective but short-term thymoleptic action. According to the proposed 
approach, fragmentation of REM sleep can be just as effective. If it really turns out 
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to be effective in alleviating depressive symptoms, then it can be relatively easily 
automated by giving the patient during REM sleep signals (for example, sound), 
selected so that they do not wake him up at all, but only wake him up, transferring 
from REM sleep to the 2nd or 1st stage of NREM sleep. Such a procedure, which is 
much more easily tolerated by patients, will also be suitable for chronic use.
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